The "GLP-1 face": what the studies show and what the aesthetic physician can offer

The benefit first

Weight loss is the benefit. In STEP 1, semaglutide 2.4 mg weekly was associated with a mean 14.9% weight reduction at 68 weeks vs 2.4% with placebo¹. In SURMOUNT-1, tirzepatide 15 mg reached −20.9% at 72 weeks vs −3.1% with placebo, and 57% of those on that dose lost 20% or more of their body weight². The semaglutide and tirzepatide pages summarize their structure and major trials.

Weight loss of that size, once seen only after bariatric surgery, also changes the face. The media called it "Ozempic face". A systematic review of 23 plastic surgery articles found that online searches for the term were linked to rising searches for "face filler" and "plastic surgeons"⁶. For the dermatologist, plastic surgeon and aesthetic physician, it is a manageable consequence and a demand that arrives at their practice.

What imaging measures: 7% per 10 kg

The first quantitative data come from a retrospective Vanderbilt study of 20 patients who had head and neck CT or MRI before and after starting a GLP-1 agonist³. With a mean weight loss of 11.0 kg over about 321 days, total midfacial volume fell by a median 9.0%: 11.0% in superficial fat and 7.0% in deep fat³. Weight loss correlated with superficial, not deep, volume loss, and regression estimated 7% less midfacial volume for every 10 kg lost³.

Drug effect or weight-loss effect?

The key question for the physician is whether a "GLP-1 face" exists that differs from the face of any major weight loss. A survey of 1,226 patients in a weight-management program showed a clear link to magnitude: among those who lost more than 20% of body weight, 72% reported skin sagging and 50% decreased facial volume; among those who lost less than 10%, 15% and 13%⁴. The authors note that greater weight loss occurred more often with GLP-1s than with other treatments⁴.

No imaging studies were found comparing the face after GLP-1s with the face after equivalent loss from diet or surgery. The prudent reading is to treat the "GLP-1 face" as the face of rapid, substantial weight loss⁵.

Skin and hair

In the same survey, 52% of those who lost more than 20% of body weight reported hair loss, vs 17% of those who lost less than 10%⁴. A meta-analysis of nine interventional studies (4,114 GLP-1 users) found more hair loss than with placebo (RR 3.25; 95% CI 1.44-7.36), with an event rate of 3.9%⁹. Another meta-analysis, pooling cohort and pharmacovigilance data, associated these drugs with a 40% increase in non-scarring alopecia (OR 1.40), driven by telogen effluvium and androgenetic alopecia; alopecia areata was not associated¹⁰. Its authors attribute this mainly to weight-loss-related micronutrient deficiency and recommend counseling and nutritional optimization rather than premature drug discontinuation¹⁰.

There is good news for the dermatologist too. Among surveyed GLP-1 users, improvement was reported by 87% of those with hidradenitis suppurativa (13 of 15), 47% of those with psoriasis and 41% of those with acne⁴. These are patient-reported data without a control group⁴. For bone, micronutrients and lean mass, see GLP-1s: muscle, rebound, eyes and pancreas.

What patients ask for: the ASPS numbers

The 2025 statistics report of the American Society of Plastic Surgeons (ASPS) devoted a chapter to GLP-1s. 82% of its surgeons received consultation requests related to these drugs⁷. For the face, the most cited were facelift (71%), neck lift (64%), eyelid surgery (37%) and brow lift (19%); for the body, tummy tuck (88%) and breast surgery (87%)⁷. Facial fat grafting was the fastest-growing cosmetic surgical procedure: up 39%, to 34,117 cases⁷. For facial rejuvenation, surgeons cited hyaluronic acid fillers first (69%), then autologous fat grafting (49%)⁷.

The report itself cautions that "consultations and procedures are not synonymous": tummy tuck was the most frequent consultation, yet its volume grew only 2%⁷. In a survey of 406 aesthetic professionals, the number of patients on GLP-1s rose by a mean 137% from 2023 to 2024; midface volume loss and face/neck laxity were the changes most cited⁸.

The responses studied and their level of evidence

• Hyaluronic acid and poly-L-lactic acid (PLLA). In a multicenter Latin American series of 15 women aged 30 to 50, with 17.9% weight loss, the combination was associated with improvement of the facial laxity scale from 4.5 to 2.6 and of the wrinkle scale from 3.1 to 1.9 at 85-100 days; 87% were satisfied and only transient bruising and edema occurred¹¹. It is a retrospective series without a control group, and several authors disclose ties to the manufacturer¹¹. In the professional survey, hyaluronic acid was considered the best facial treatment for an average 47% of patients⁸.
• Calcium hydroxylapatite (CaHA) and prevention. A "virtual" trial with 12,000 digital twins predicted that all preventive injectables reduced sagging; CaHA the most (−2.74 mm), and hyaluronic acid with an early effect that attenuated (−1.11 mm)¹². The authors stress these are model predictions, not clinical evidence¹².
• Autologous fat grafting. It is the fastest-growing technique⁷, but a scoping review found no clinical or preclinical study that directly measured graft outcomes in patients on incretins; the concerns are mechanistic and its recommendations hypotheses¹³.

Fasting and sedation management is covered in A full stomach despite fasting.

The body: contouring after major weight loss

In a matched TriNetX analysis, GLP-1 users who had surgery chose breast procedures more often than post-bariatric patients (56.9% vs 21.7%), while the latter more often had abdominal procedures (84.8% vs 42.1%)¹⁴. GLP-1 users had less intraoperative hemorrhage (0.07% vs 0.74%) and similar rates of infection, dehiscence and thromboembolism¹⁴. In a cohort of 552 patients, greater and faster weight loss predicted more seromas and complications, especially with combined bariatric surgery and GLP-1s¹⁵. A recent review concludes that GLP-1 use is neither an absolute advantage nor an automatic contraindication: weight stability and nutritional status are among the factors that count⁵.

Where the evidence ends

Almost everything published consists of case series, surveys, narrative reviews and expert opinion⁵⁶. The only imaging study has 20 patients and is retrospective³. The filler series has 15 patients and industry support¹¹, and the biostimulator trial is a simulation¹². Systematic reviews acknowledge biases in the available literature⁶. Prospective studies comparing techniques and timing of intervention are lacking⁵.